Merck & Co. stock is at EUR 131.82 pre-market at Lang & Schwarz at 8:28 a.m. CEST on September 30, 2

Merck & Co. stock trades at EUR 131.05 at Lang & Schwarz on September 29, 2026, plus 0.54 percent ve

Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after platinum-based chemotherapy. Following FDA discussions, the partners said the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements. The investment […]

Scotiabank elevó su precio objetivo para las acciones de Merck & Co., Inc. de $155,00 a $180,00 y otorgó a la compañía una calificación de "desempeño superior del sector" en un informe del martes.

Merck & Co. stock last traded at USD 148.69 on September 28, 2026. The company announced a global li

Merck's Sept. 28 licence for preclinical KRAS G12D drug SPR2015 includes US$400M upfront and conditional milestone payments.

Las acciones de Merck & Co. cotizaban a 148,74 dólares el 25 de septiembre de 2026, con una capitalización de mercado de 367,4 mil millones de dólares. gugg

El segundo medicamento candidato del mega acuerdo ADC de Merck & Co. con Daiichi Sankyo se ha topado con un obstáculo con la FDA de EE. UU., después de que la agencia considerara que su BLA era insuficiente para una aprobación acelerada. Las esperanzas ahora están puestas en el ensayo de fase III IDeate-Lung02.

On September 24, Merck & Co., Inc. (NYSE:MRK) announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig, a potentially first-in-class tri-specific Wnt pathway agonist, in adults with diabetic macular edema (DME). At 52 weeks, both the 0.5 mg and 0.8 mg doses met the primary endpoint by demonstrating non-inferiority to the […]

Merck and Daiichi Sankyo withdrew the ifinatamab BLA on Sept. 25 after FDA discussions; the Oct. 10 action date had been set.

Merck & Co. stock opened at USD 148.06, reached USD 149.94 and fell to USD 147.48 before trading at

Merck stock follows Q2 revenue of USD 16.61 billion on August 4, 2026. Adjusted EPS beat consensus b